A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Linezolid; Linezolid
- Indications Bacterial infections; Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Acronyms OASIS; OASIS-1
- Sponsors Paratek Pharmaceuticals
- 11 Jan 2022 Results of pool and post hoc analysis from the Phase 3 studies (NCT02378480 and NCT02877927) assessing the efficacy and safety of omadacycline, versus linezolid, in PWID subgroup and non-PWID subgroup, in acute skin and skin structure infection, published in the Infectious Diseases and Therapy.
- 17 Jan 2021 Results of post-hoc secondary analysis from OASIS-1 and OASIS-2 published in the Journal of Antimicrobial Chemotherapy
- 27 Apr 2020 Results published in the Antimicrobial Agents and Chemotherapy